Adolescent Idiopathic Scoliosis (AIS)MID-CNCT02200302
Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
An observational study of Adolescent Idiopathic Scoliosis (AIS), run by Apifix at 1 site in France.
Trial summary
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle . Read more about this study
- Who is it for?
- Ages 11 to 20 years
- Conditions the study is for
- Adolescent Idiopathic Scoliosis (AIS)
- How many people
- 2 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2014to May 2016
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 20 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: The study is designed as a European, observational study with a 12-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 6-month enrollment period.
Who may be able to join
- 11≤ Adolescents < 20 years old
- Patient undergoing treatment of AIS by the MID-C system in daily practice
- Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5
- Flexible major curve, correction to below 30° at lateral bending.
- Risser sign of 1 to 5
- Appropriate candidate for posterior surgical approach as determined by surgeon
Show all 9Show fewer
- Subject has good general health as determined by physician.
- Subject has no known hypersensitivity and allergies to Titanium
- Subject's guardian willing to sign a written Informed Consent Form (ICF)
Who cannot join
- Cobb angle over 60 degrees
- Other non-idiopathic scoliosis.
- AIS which is not defined as Lenke type 1 or 5
- Previous spine surgery.
- Known allergy to any component of the device.
- Known active systemic disease, such as AIDS, HIV, or active infection
- Systemic disease that would affect the subject's welfare or overall outcome of the study as determined by the physician.
- Mentally compromised as determined by the physician
Trial locations and contacts
1 site in 1 country.
About this study
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle .
The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk .
Read more
Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain.
Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential.
ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction.
The MID-C System inherent benefits are:
- Only two screws are used
- Incision size is much smaller
- Simpler operation with shorter operative time
- Less complications (attributed to the three points above).
- Minimal spinal mobility loss.
All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure).
The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years.
This study is designed to demonstrate that the MID-C System is safe and effective.
Read the detailed description
The study is designed as a European, observational study with a 12-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 6-month enrollment period.
- Conditions
- Adolescent Idiopathic Scoliosis (AIS)
What is being measured
The primary outcome is the main question the study is designed to answer.
No Device related Serious Adverse Event
Measured: 1 year
No curve progression ˃10° above or below the implant
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2014 (estimated)
- Study startOct 2014
- Primary completionMay 2016
- Study completionMay 2016
Why it stopped: lack of cooperation and compliance
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adolescent Idiopathic Scoliosis (AIS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Apifix
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- JEAN-CHARLES LE HUEC, PD Dr. med., Principal investigator, Unité d'Orthopédie-traumatologie, Rachis II
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02200302
- Sponsor's protocol ID
- AF - 02
- Acronym
- MID-C
- Status last verified
- Feb 2017
- First submitted
- 24 Jul 2014
- Last updated
- 9 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
- ClinicalTrials.gov ID
- NCT02200302
- Acronym / sponsor ID
- MID-C / AF - 02
- Conditions
- Adolescent Idiopathic Scoliosis (AIS)
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: lack of cooperation and compliance
- Enrolment
- 2 participants (actual)
- Lead sponsor
- ApifixIndustry (pharma, biotech, devices)
- Study start
- Oct 2014 (actual)
- Primary completion
- May 2016 (actual)
- Study completion
- May 2016 (actual)
- First posted
- 25 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle .
The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk .
Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain.
Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential.
ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction.
The MID-C System inherent benefits are:
- Only two screws are used
- Incision size is much smaller
- Simpler operation with shorter operative time
- Less complications (attributed to the three points above).
- Minimal spinal mobility loss.
All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure).
The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years.
This study is designed to demonstrate that the MID-C System is safe and effective.
Detailed description
The study is designed as a European, observational study with a 12-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 6-month enrollment period.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 11 to 20 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- The study is designed as a European, observational study with a 12-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 6-month enrollment period.
Key inclusion criteria (9 listed)
- 11≤ Adolescents < 20 years old
- Patient undergoing treatment of AIS by the MID-C system in daily practice
- Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5
- Flexible major curve, correction to below 30° at lateral bending.
- Risser sign of 1 to 5
Key exclusion criteria (8 listed)
- Cobb angle over 60 degrees
- Other non-idiopathic scoliosis.
- AIS which is not defined as Lenke type 1 or 5
- Previous spine surgery.
- Known allergy to any component of the device.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
No Device related Serious Adverse Event
Time frame: 1 year
No curve progression ˃10° above or below the implant
Time frame: 1 year
Results and safety
The study was stopped early (reason given: lack of cooperation and compliance). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2017.
Related trials for Adolescent Idiopathic Scoliosis (AIS)
Active, not recruiting
Diaphragm Mobilization in Adolescent Idiopathic Scoliosis
Adolescent Idiopathic Scoliosis
RecruitingObservational study
Turkish Adaptation and Validation of the Scoliosis Misconception Scale in Adolescents With Idiopathic Scoliosis
Adolescent Idiopathic Scoliosis (AIS)
Not yet recruitingObservational study
Clinical and Biological Parameters in Adolescent Idiopathic Scoliosis
Adolescent Idiopathic Scoliosis (AIS)
Active, not recruitingObservational study
Construction of a Screening and Precision Intervention System for Adolescent Idiopathic Scoliosis Based on the DIERS Spinal Moiré System
Adolescent Idiopathic Scoliosis (AIS)
Recruiting
Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
Adolescent Idiopathic Scoliosis (AIS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
JEAN-CHARLES LE HUEC, PD Dr. med. principal investigator
Unité d'Orthopédie-traumatologie, Rachis II
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adolescent Idiopathic Scoliosis (AIS), run by Apifix at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: lack of cooperation and compliance). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
No Device related Serious Adverse Event (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2017.